ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (29, Figure 7), as the first tyrosine kinase inhibitor (TKI) and the first-generation ABL inhibitor, has achieved significant clinical effects and is used as a first-line treatment for CML patients.